Genovate Biotechnology Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was TWD 99.67 million compared to TWD 103.55 million a year ago. Net loss was TWD 9.39 million compared to net income of TWD 8.65 million a year ago.

Basic loss per share from continuing operations was TWD 0.09 compared to basic earnings per share from continuing operations of TWD 0.08 a year ago. Diluted loss per share from continuing operations was TWD 0.09 compared to diluted earnings per share from continuing operations of TWD 0.08 a year ago. Basic loss per share was TWD 0.09 compared to basic earnings per share of TWD 0.08 a year ago.

Diluted loss per share was TWD 0.09 compared to diluted earnings per share of TWD 0.08 a year ago.